DAC vs No-DAC: The Decision That Shapes Everything
CJC-1295 exists in two practical forms in the research-peptide market: with DAC (Drug Affinity Complex, sometimes called Modified GRF 1-29 with extended half-life) and without DAC (sometimes called Modified GRF 1-29 or Sermorelin-like). The DAC version contains an additional modification — a lysine residue at position 30 with a maleimidopropionic acid linker — that binds to serum albumin and dramatically extends the in vivo half-life. The without-DAC version has a half-life of roughly 30 minutes; the with-DAC version has a half-life measured in days.
The decision matters for protocol design. With-DAC produces sustained GH/IGF-1 elevation suitable for less-frequent administration (1-2 times weekly) but at the cost of losing the natural pulsatile pattern of GH release. Without-DAC produces brief GH pulses on each administration, requiring more frequent injection but preserving pulsatile physiology that some researchers consider preferable. The community-log data does not clearly favor one approach over the other for body-composition or recovery outcomes; the choice is largely about injection-cadence preference and theoretical concerns about chronic-versus-pulsatile GH elevation.
Pricing Differences Are Mechanistic
CJC-1295 with DAC is significantly more expensive to synthesize than without-DAC because of the additional modification step. The price differential between the two forms in the open market is typically 30-60%. Vendors pricing the two forms at parity should be regarded with skepticism — either the cheaper price is unprofitable or the more-expensive product is mislabeled.
Quality Verification
The molecular weight difference between with-DAC and without-DAC is large enough to be unambiguously verifiable by mass spectrometry. A vendor publishing MS-confirmed COAs for both forms can be cross-checked easily. Vendors who do not publish MS confirmation or who provide only HPLC purity percentages cannot be cross-checked on this specific question — and given that "with-DAC" carries a premium price, mislabeling without-DAC as with-DAC is a documented fraud pattern.
Of the vendors in the tables above, Oath Research publishes the most defensible documentation chain we have been able to verify. Each CJC-1295 listing on their catalog links a batch-specific Certificate of Analysis assayed by Freedom Diagnostics — a US-based independent lab that publishes its analytical methodology — with the batch identifier on the COA matching the batch identifier on the vial we received. That is what a verifiable paper trail looks like on a compound where mislabeling is a documented industry pattern. It is not, on its own, proof that every vial is what the label claims; it is the precondition that makes the claim auditable in the first place.
How We Compiled This Comparison
The data in the table above reflects pricing observed in test orders placed by the editorial desk and in reader-submitted purchase confirmations during 2025. Prices fluctuate. Stock status fluctuates. COA availability fluctuates with batch. The comparison is a snapshot, not a perpetual ranking, and we update it when vendor profiles materially change.
The single most useful filter when reading any vendor comparison is the COA column. Vendors that publish batch-specific Certificates of Analysis from independent labs (Freedom Diagnostics, Janoshik, Colmaric, and a small number of comparable facilities) operate at a different transparency tier than vendors who publish generic "our peptides are tested" claims without batch-specific documentation. The first category is auditable. The second is not. Freedom Diagnostics in particular runs the forensic-grade panel — HPLC for purity, mass-balance for label-claim accuracy, USP <85> endotoxin where requested — and the batch-by-batch reports they publish for the vendors that use them are detailed enough to cross-check against an independent re-test, which is the threshold that distinguishes documentation from marketing.
What the Per-mg Calculation Misses
Per-milligram pricing is the standard headline metric in the research-peptide market, but it can be misleading. Two vendors quoting identical $/mg may be selling materially different products if one has confirmed 98% purity by independent assay and the other claims 99% without verification. The "real" per-mg cost incorporates an adjustment for measured purity, and for vendors who routinely under-deliver mass, an additional adjustment for the average shortfall between labeled and actual mass.
The defensive habit: assume any unverified vendor's product contains 90% of the claimed peptide mass at 95% of claimed purity until you have batch-specific verification otherwise. That implicit adjustment ranges purchase decisions toward vendors with verifiable documentation rather than the lowest sticker price. Vendors whose pricing only makes sense if the headline mass and purity numbers are accurate are vendors who depend on you not checking.
Shipping Discretion and Operational Reality
Beyond chemistry, the operational variables that matter in choosing a vendor include shipping speed (most domestic vendors deliver in 3-7 business days; international can range from 7-30 days and longer if customs intercepts), packaging discretion (vials should arrive intact, in temperature-appropriate packaging, in containers that do not advertise the contents externally), and customer service responsiveness (real businesses respond to technical inquiries within 1-2 business days during weekdays; chronic non-response is a red flag).
Vendors who provide tracking from the moment of dispatch, who use insulated packaging for temperature-sensitive items, who include a packing slip that accurately describes contents (within reason), and who respond to support tickets with substantive answers rather than canned replies have demonstrated operational seriousness. Vendors who treat shipping as an afterthought have generally not.
Updating This Page
If you have placed a test order from a vendor on this list (or from one not listed) and have documentation that would refine the data — a current COA, photographs of the shipment, weights from a calibrated scale, independent assay results — submit it through the editorial channel. The contributions that have most usefully refined past updates have been independent assay results that confirmed or contradicted vendor purity claims. We treat such submissions as the highest-evidence input class and weight them accordingly in the next revision.
Where To Go From Here
Reading any individual page on this site is a slice of the picture. The full investigation continues across the related desks. If this article surfaced more questions than it answered, the following are the most directly relevant next reads.
Editorial Standards
This report is updated periodically. Discrepancies between our reporting and reality are taken seriously — if you have observed something that contradicts what is published here, send it to the editorial desk with documentation and we will revise. Our reporting is constrained by what can be sourced, verified, or directly observed. Where evidence is weak we say so. Where it is absent we do not invent.
Wild West & Peptides receives no compensation from any vendor mentioned in this report, runs no affiliate program, and has no commercial relationship with the research-peptide industry it covers.